Latest News
CeleCor Therapeutics submits final section of zalunfiban (Disaggpro) New Drug Application to US FDA
25 June 2026 - US pharmaceutical company CeleCor Therapeutics said on Wednesday that it has submitted the final section of its New Drug Application (NDA) for the company's investigational heart-attack drug, zalunfiban (Disaggpro), to the US Food...
Biosidus partners with Mubadala Bio in the UAE
25 June 2026 - Biosidus, an Argentina-based biotechnology company, announced on Wednesday the signing of a licensing and supply agreement with Mubadala Bio, the life sciences platform of Mubadala Investment Company, to introduce a portfolio of biolog...
Vascarta announces VAS-101 Phase I results in sickle cell disease patients
25 June 2026 - Clinical-stage biopharmaceutical company Vascarta Inc announced on Wednesday the successful completion of the sublingual arm of its Phase I clinical trial evaluating VAS-101 (Vasceptor; topical curcumin gel) for the treatment of sickle...
Cirius Therapeutics commences enrolment and dosing for Phase 2 study of CIR-0602K in type 1 diabetes
25 June 2026 - Cirius Therapeutics Inc, a developer of innovative therapies for people suffering from diseases caused by mitochondrial dysfunction and insulin resistance, announced on Wednesday that enrolment and dosing has begun in a Phase 2 clinica...
Lundbeck to present new Vyepti and bocunebart migraine data at EAN 2026
24 June 2026 - Biopharmaceutical company H. Lundbeck A/S (XCSE: HLUN A) reported on Wednesday that it will present new clinical data from its migraine portfolio at the European Academy of Neurology (EAN) Congress 2026 in Geneva, highlighting both app...